Kuros Biosurgery Closes Acquisition of Cytos Biotechnology, Renamed Kuros Biosciences

Kuros Biosciences Ltd. (SIX:KURN) closed its acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd.
According to the press release:

Starting 20 January 2016 all 508,432,244 Kuros Biosciences Ltd. shares are listed and freely tradable under the ticker symbol KURN on the SIX Swiss Exchange under the International Reporting Standard and include all former 108’015’276 Cytos Biotechnology AG shares, which remain listed and freely tradable under the unchanged ISIN number (CH0011025217).

Christian Itin, Chairman of Kuros Board of Directors, stated:

We are pleased with the successful closing of the business combination and welcome our new shareholders. Kuros’ product candidates address important markets in wound care and bone regeneration. We are excited about the potential to create long-term value for shareholders.

Click here to view the full press release.